Skip to search formSkip to main contentSkip to account menu

AMG 386

Known as: AMG-386, AMG386, Angiopoietin 1/2-Neutralizing Peptibody AMG 386 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

trebananib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Controlling Arteriogenesis and Mast Cells Are Central to Bioengineering Solutions for Critical Bone Defect Repair Using Allografts
Although most fractures heal, critical defects in bone fail due to aberrant differentiation of mesenchymal stem cells towards… 
2014
2014
508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041)
2014
2014
A phase 1b trial of AMG386 and temsirolimus in patients with advanced solid tumor
Review
2013
Review
2013
Targeting angiopoietin-2 signaling in cancer therapy
Introdcution: Over the past decade, several anti-angiogenic strategies have been devised to target a wide spectrum of… 
2013
2013
Abstract 4647: Tie2-expressing monocytes (TEMs) as potential biomarkers of angiopoietin-Tie2 (Ang/Tie2) directed therapies: correlative analysis of a phase I study of AMG386 + temsirolimus (T).
Background: The Ang/Tie2 pathway plays a critical role in tumor angiogenesis, and several agents targeting this axis are in… 
2013
2013
Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS).
TPS10592 Background: Angiosarcomas (ASs) are rare, aggressive, malignant endothelial cell tumors that constitute 1% to 2% of all… 
2013
2013
A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children's Oncology Group Phase 1 Consortium report.
2538 Background: Trebananib is a first-in-class peptibody (peptide-Fc fusion protein) that selectively inhibits Angiopoietin 1… 
Review
2012
Review
2012
[Adverse event profile of new targeted agents for renal cell carcinoma].
Targeted therapy has survival benefit for patients with advanced renal cell carcinoma. However, intolerability often causes… 
2011
2011
Abstract 3280: Phase 1 study of AMG 386, an anti-angiogenic Fc fusion protein targeting angiopoietin-1 and -2, in Japanese patients with advanced solid tumors
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: AMG 386, a first-in-class investigational… 
2009
2009
Avastin-Tarceva combination fails in lung cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)